TARGETgeneHomo sapiens
CFL1
Linked hypotheses (20)
- CFL1 × TP53 interaction (auto-validated BOLTZ2_PPI iPTM=0.91)mechanismconf 91%
- CFL1 × NRG1 interaction (auto-validated BOLTZ2_PPI iPTM=0.91)mechanismconf 91%
- CFL1 × SMN1 interaction (auto-validated BOLTZ2_PPI iPTM=0.90)mechanismconf 90%
- [Gene Expression] LIMK2 is implicated in SMA pathogenesis based on 138 converging claimstargetconf 88%
- [Gene Expression] LIMK2 is implicated in SMA pathogenesis based on 138 converging claimstargetconf 88%
- [Gene Expression] LIMK2 is implicated in SMA pathogenesis based on 138 converging claimstargetconf 88%
- [Gene Expression] LIMK2 is implicated in SMA pathogenesis based on 138 converging claimstargetconf 88%
- [Gene Expression] LIMK2 is implicated in SMA pathogenesis based on 138 converging claimstargetconf 88%
- [Gene Expression] LIMK2 is implicated in SMA pathogenesis based on 138 converging claimstargetconf 88%
- [Gene Expression] LIMK2 is implicated in SMA pathogenesis based on 138 converging claimstargetconf 88%
- [Gene Expression] LIMK2 is implicated in SMA pathogenesis based on 138 converging claimstargetconf 88%
- [Gene Expression] LIMK2 is implicated in SMA pathogenesis based on 138 converging claimstargetconf 88%
- [Gene Expression] LIMK2 is implicated in SMA pathogenesis based on 138 converging claimstargetconf 88%
- [Gene Expression] LIMK2 is implicated in SMA pathogenesis based on 138 converging claimstargetconf 88%
- [Gene Expression] LIMK2 is implicated in SMA pathogenesis based on 138 converging claimstargetconf 88%
- [Gene Expression] LIMK2 is implicated in SMA pathogenesis based on 138 converging claimstargetconf 88%
- [Gene Expression] LIMK2 is implicated in SMA pathogenesis based on 138 converging claimstargetconf 88%
- [Gene Expression] LIMK2 is implicated in SMA pathogenesis based on 138 converging claimstargetconf 88%
- [Gene Expression] LIMK2 is implicated in SMA pathogenesis based on 138 converging claimstargetconf 88%
- [Gene Expression] LIMK2 is implicated in SMA pathogenesis based on 138 converging claimstargetconf 88%
Top compound hits (10)
| Compound ID | SMILES | Score | Tier |
|---|---|---|---|
| DMP_840 | Nc1ccc2ccc3ccc(N)cc3c2c1 | 0.638 | early |
| simon_handoff_A3_CFL_CFL1_r1_4901818ac0 | Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2c(OC(C)C)nncc2c1 | 0.624 | early |
| simon_handoff_A3_CFL_CFL1_r2_e7c8009dfa | Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2c(c1)NC(=O)C21CCC(O)CC1 | 0.619 | early |
| simon_handoff_A3_CFL_CFL1_r3_58f956e4a4 | CN(c1ccccc1)c1ccc2nc(N)nc(N)c2n1 | 0.604 | early |
| simon_handoff_A3_CFL_CFL1_r4_0347044c17 | CN1CCC(c2[nH]nc(-c3ccc(Cl)cc3)c2-c2ccncc2)CC1 | 0.571 | early |
| simon_handoff_A3_CFL_CFL1_r5_2df023f48e | CN1c2cc(-c3ccncc3)sc2C(=O)NC1(C)C | 0.563 | early |
| simon_handoff_A3_CFL_CFL1_r6_dfb62dec0e | Cc1c(Br)c(Br)c2c3c1nc(N1CCNCC1)n3CCC2 | 0.557 | early |
| Branaplam | Cc1cnc(C2=NC(=O)c3ccc(NCCN(C)C)cc3O2)nc1 | 0.541 | early |
| simon_handoff_A3_CFL_CFL1_r7_ea32f83079 | Nc1nc(N)c2c(n1)CCC(Cc1ccccc1)C2 | 0.518 | early |
| simon_handoff_A3_CFL_CFL1_r8_10535e8d5e | Nc1nc(N)c2c(n1)CCC(Cc1cccs1)C2 | 0.501 | early |
Linked claims (9)
| Type | Predicate | Conf | Source |
|---|---|---|---|
| protein interaction | boltz2_ppi_iptm | 16% | — |
| protein interaction | boltz2_ppi_iptm | 15% | — |
| protein interaction | boltz2_ppi_iptm | 14% | — |
| protein interaction | boltz2_ppi_iptm | 14% | — |
| protein interaction | boltz2_ppi_iptm | 13% | — |
| protein interaction | boltz2_ppi_iptm | 12% | — |
| protein interaction | boltz2_ppi_iptm | 12% | — |
| other | depmap_delta_dependency | 10% | — |
| protein interaction | boltz2_ppi_iptm | 10% | — |